These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Molecular evaluation of ablative therapy of Barrett's oesophagus. Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364 [TBL] [Abstract][Full Text] [Related]
4. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling. Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019 [TBL] [Abstract][Full Text] [Related]
5. Barrett's oesophagus: the new endoscopic modalities have a future. Deviere J Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i33-7. PubMed ID: 15711006 [TBL] [Abstract][Full Text] [Related]
6. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus. Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678 [TBL] [Abstract][Full Text] [Related]
7. Cancer risk in Barrett's oesophagus. Dias Pereira A; Suspiro A; Chaves P Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157 [TBL] [Abstract][Full Text] [Related]
8. Barrett's esophagus: a retrospective analysis of 13 years surveillance. Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769 [TBL] [Abstract][Full Text] [Related]
9. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma. Yamamoto S; Kijima H; Hara T; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H Int J Mol Med; 2005 Sep; 16(3):375-80. PubMed ID: 16077942 [TBL] [Abstract][Full Text] [Related]
10. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence. Gleeson CM; Sloan JM; McGuigan JA; Ritchie AJ; Weber JL; Russell SE Genes Chromosomes Cancer; 1998 Jan; 21(1):49-60. PubMed ID: 9443041 [TBL] [Abstract][Full Text] [Related]
11. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963 [TBL] [Abstract][Full Text] [Related]
12. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus. Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858 [TBL] [Abstract][Full Text] [Related]
13. Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression. Doak SH; Jenkins GJ; Parry EM; Griffiths AP; Baxter JN; Parry JM Mutat Res; 2004 Mar; 547(1-2):133-44. PubMed ID: 15013707 [TBL] [Abstract][Full Text] [Related]
14. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management. Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948 [TBL] [Abstract][Full Text] [Related]
15. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report. Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596 [TBL] [Abstract][Full Text] [Related]
16. Aurora kinase A in Barrett's carcinogenesis. Rugge M; Fassan M; Zaninotto G; Pizzi M; Giacomelli L; Battaglia G; Rizzetto C; Parente P; Ancona E Hum Pathol; 2010 Oct; 41(10):1380-6. PubMed ID: 20656315 [TBL] [Abstract][Full Text] [Related]